Anavex Life Sciences said European regulators informed it of a negative trend vote related to its application for its blarcamesine treatment of early Alzheimer's disease. The Committee for Medicinal ...

Washington University Medicine in St. Louis is conducting important research into treating early-onset Alzheimer's before ...

A team of researchers at the Federal University of ABC (UFABC) in Brazil has developed a new chemical compound with the ...

In a new study, scientists discovered two FDA-approved cancer drugs that could also be effective at combatting one well-known ...

A new study shows that lecanemab, an amyloid-clearing Alzheimer’s therapy, does not improve the brain’s waste-removal network ...

The latest update is out from BioArctic AB Class B ( ($SE:BIOA.B) ).

Researchers found that lecanemab, the Alzheimer’s drug designed to clear amyloid-β plaques, does not improve the brain’s waste clearance system in the short term.

The daily rhythm of genetic activity varies between individual cell types in ways that depend on their states of health, a ...

The new treatment approach targets restoring normal blood vessel function instead of focusing on neurons or other brain cells, which has been the common strategy until now. A team of scientists co-led ...

November is Alzheimer's Awareness Month, and we want to take this time to learn more about this disease that affects so many ...

Anavex Life Sciences Corp. ("Anavex” or the "Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

A newly approved blood test can help rule out some cases based on the amount of amyloid in the brain. A neurology professor ...